A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy

E. Miyahara, W. Takiyama, N. Sakamoto, T. Azuma, R. Ohashi, Y. Kirihara, H. Doihara, N. Yokoyama, M. Tanada, H. Soga, A. Kurita, H. Saeki, S. Takashima, K. Mandai

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here. The patients received four courses of 5-FU (370 mg/m2/day, for five days, continuous infusion), ADM (30 mg/m2 on day 1, i.v.) and CDDP (55 mg/m2 on day 1, i.v.) every 3 weekks in our hospital. This was followed by 7 months of outpatient therapy with 5-FU (550 mg/m2 on day 1, i.v.), ADM (30 mg/m2 on day 1, i.v.) and CBDCA (330 mg/m2 on day 1, i.v.) for every 4 weeks. The complete remission of the primary and metastatic lesions, that was confirmed by the histological examinations, was obtained after 10 months since the initial treatment started. The toxicity was generally moderate, however, the alopecia was severe. The patient has been living for 6 months without any signs of the recurrence after the complete remission obtained.

Original languageEnglish
Pages (from-to)643-646
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Issue number5
Publication statusPublished - Jan 1 1993
Externally publishedYes


  • 5-fluorouracil
  • carboplatin
  • cisplatin
  • doxorubicin
  • gastric cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy'. Together they form a unique fingerprint.

Cite this